29 related articles for article (PubMed ID: 7732561)
1. Viral prophylaxis in organ transplant patients.
Slifkin M; Doron S; Snydman DR
Drugs; 2004; 64(24):2763-92. PubMed ID: 15563248
[TBL] [Abstract][Full Text] [Related]
2. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Hebart H; Kanz L; Jahn G; Einsele H
Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
[TBL] [Abstract][Full Text] [Related]
3. Lung transplantation. Part II. Postoperative management and results.
Wood DE; Raghu G
West J Med; 1997 Jan; 166(1):45-55. PubMed ID: 9074338
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
6. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
7. Impact of cytomegalovirus match on survival after cardiac and lung transplantation.
Bonatti H; Tabarelli W; Ruttmann E; Kafka R; Larcher C; Höfer D; Klaus A; Laufer G; Geltner C; Margreiter R; Müller L; Antretter H
Am Surg; 2004 Aug; 70(8):710-4. PubMed ID: 15328806
[TBL] [Abstract][Full Text] [Related]
8. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients.
Kelly JL; Albert RK; Wood DE; Raghu G
Transplantation; 1995 Apr; 59(8):1144-7. PubMed ID: 7732561
[TBL] [Abstract][Full Text] [Related]
10. Recurrent cytomegalovirus disease in solid-organ transplant recipients.
Falagas ME; Snydman DR
Transplant Proc; 1995 Oct; 27(5 Suppl 1):34-7. PubMed ID: 7482815
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infections in heart and heart-lung transplant recipients.
Wreghitt T
J Antimicrob Chemother; 1989 Jun; 23 Suppl E():49-60. PubMed ID: 2550412
[TBL] [Abstract][Full Text] [Related]
12. [Risk factors for cytomegalovirus in solid organ transplant recipients].
Cervera C; Gurguí M; Lumbreras C
Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 6():11-7. PubMed ID: 22541916
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
